Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard of care therapy Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Interpersonal Therapy-Based Treatment to Prevent Postpartum Depression in Adolescent Mothers

NCT01482832
View directory record Official record
Conditions
Postpartum Depression
Interventions
Interpersonal therapy-based treatment
Behavioral
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
12 Years to 19 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 28, 2026, 9:23 PM EDT
Not listed Phase 2 Interventional

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

NCT02446093
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma
Interventions
Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy, Surgery
Biological · Radiation · Procedure
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Fort Myers, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 28, 2026, 9:23 PM EDT
Completed No phase listed Observational

Inter-Disciplinary Outpatient Care Model Providing Comprehensive Geriatric Assessment, Care-Coordination & Co-management

NCT04846049
View directory record Official record
Conditions
Veterans, Geriatric Assessment, Care-Coordination, Outpatient Care
Interventions
Comprehensive Care, Standard Care
Other
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
65 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 28, 2026, 9:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

NCT06293638
View directory record Official record
Conditions
Essential Tremor
Interventions
Alcohol, Alprazolam, Cold Therapy, Peripheral Nerve Stimulation
Drug · Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 28, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

NCT06319248
View directory record Official record
Conditions
Sepsis, Low Blood Pressure
Interventions
Midodrine, Standard of Care
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 28, 2026, 9:23 PM EDT
Completed No phase listed Observational

DUCATS Trial: Dynamic Ultrasound to Enhance Understanding of Carpal Tunnel Syndrome

NCT02219555
View directory record Official record
Conditions
Carpal Tunnel
Interventions
Steroid Injection, Carpel Tunnel surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Phase 4 Interventional Results available

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

NCT01825408
View directory record Official record
Conditions
Sinusitis
Interventions
Doxycycline, Azithromycin, Augmentin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Not applicable Interventional

E-Health Support Program (PACK Health Program) in Supporting Patient Reported Symptoms in Newly Diagnosed Patients With Breast Cancer

NCT05549687
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Questionnaire Administration, Supportive Care
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 28, 2026, 9:23 PM EDT
Active, not recruiting Phase 1 Interventional

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT03587038
View directory record Official record
Conditions
Glioblastoma
Interventions
OKN 007, Temozolomide, Photon/Proton IMRT
Drug · Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Phase 1Phase 2 Interventional

BATs Treatment for Pancreatic Cancer, Phase Ib/II

NCT03269526
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Interventions
EGFR BATs after standard of care chemo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Not applicable Interventional

Nativis Voyager for Newly Diagnosed GBM

NCT03276286
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nativis Voyager
Device
Lead sponsor
Nativis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tucson, Arizona • Encinitas, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Phase 4 Interventional

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

NCT05772169
View directory record Official record
Conditions
Hypercortisolism, Diabetes Mellitus, Type 2
Interventions
Mifepristone 300 MG [Korlym], Placebo for mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Escondido, California • Gardena, California • Huntington Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

NCT00679354
View directory record Official record
Conditions
Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
cilengitide, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 28, 2026, 9:23 PM EDT
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
4
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

NCT04663737
View directory record Official record
Conditions
Covid19
Interventions
Silmitasertib, SOC
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 28, 2026, 9:23 PM EDT
Terminated No phase listed Observational

A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

NCT05026502
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 28, 2026, 9:23 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Steroids for Early Treatment of Radiation Retinopathy

NCT03238157
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
Fluocinolone Acetonide (FA) implant
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Not applicable Interventional

Gaze and Postural Stability in Multiple Sclerosis

NCT03521557
View directory record Official record
Conditions
Multiple Sclerosis, Vertigo, Dizziness, Falls Injury
Interventions
Gaze and Postural Stability, Standard Care Control
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
20 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 28, 2026, 9:23 PM EDT
Terminated No phase listed Observational

VIZ ACCESS HCM - Multi-Site Registry

NCT07103057
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Viz HCM
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Evanston, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 9:23 PM EDT
Terminated No phase listed Observational

Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

NCT03768765
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Holmium Laser Prostate Surgery
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

NCT05045183
View directory record Official record
Conditions
Wound Healing
Interventions
SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 28, 2026, 9:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

NCT01506141
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT, Elaprase
Drug
Lead sponsor
Takeda
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 28, 2026, 9:23 PM EDT
Recruiting Not applicable Interventional

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

NCT05793151
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
Interventions
ENDURE
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
St Louis, Missouri • Durham, North Carolina • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 28, 2026, 9:23 PM EDT